Beijing Hotgen Biotech Co

Beijing Hotgen Biotech Co FCF Yield

The Free Cash Flow Yield of Beijing Hotgen Biotech Co (688068.SS) as of Nov 5, 2026 is -1.11 %. In the previous year, Free Cash Flow Yield was -0.77 % — a change of 43.31% (lower).

FCF Yield

-1.11 %

YoY

43.31%

Last updated:

Free Cash Flow Yield of Beijing Hotgen Biotech Co is 2025 -1.11 % . Free Cash Flow Yield of Beijing Hotgen Biotech Co was 2024 -0.77 % . It decreases by 43.31% lower compared to the previous year.

The Beijing Hotgen Biotech Co FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
0.11 CNY
Jan 1, 2019
-0.60 CNY
Jan 1, 2020
-0.07 CNY
Jan 1, 2021
19.55 CNY
Jan 1, 2022
3.60 CNY
Jan 1, 2023
-3.82 CNY
Jan 1, 2024
-0.77 CNY
Jan 1, 2025
-1.11 CNY
The Beijing Hotgen Biotech Co FCF Yield history
YEARFCF YieldYoY
-1.11 %+43.31%
-0.77 %-79.81%
-3.82 %-206.10%
3.60 %-81.58%
19.55 %-29,470.94%
-0.07 %-88.94%
-0.60 %-630.25%
0.11 %-128.27%
-0.40 %-289.24%
0.21 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beijing Hotgen Biotech Co Stock analysis

What does Beijing Hotgen Biotech Co do? Beijing Hotgen Biotech Co., Ltd. generates revenue through the development and manufacturing of in-vitro diagnostic, point-of-care-testing, and biodefense products. The firm's product portfolio primarily consists of in vitro diagnostic reagents, in vitro diagnostic instruments, and biological raw materials. These offerings are designed to address clinical needs in areas such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections. Additionally, the products serve public safety applications including biosafety, food safety, and disease control and emergency response. The company operates in both domestic and overseas markets, selling its solutions to entities involved in clinical healthcare and public safety sectors. By providing specialized diagnostic tools and biological materials, Beijing Hotgen Biotech Co., Ltd. supports medical diagnosis and emergency response efforts globally. The business model relies on the direct sale of these manufactured goods to customers who require advanced diagnostic capabilities for disease detection and safety monitoring. Beijing Hotgen Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beijing Hotgen Biotech Co stock

Free Cash Flow Yield of Beijing Hotgen Biotech Co is -1.11 % in 2025.

Free Cash Flow Yield of Beijing Hotgen Biotech Co changed from -0.77 % to -1.11 %, representing a 43.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Beijing Hotgen Biotech Co since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Beijing Hotgen Biotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Beijing Hotgen Biotech Co

All Key Metrics — Beijing Hotgen Biotech Co